Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.

Heterologous prime-boost vaccination using plasmid DNA followed by replication-defective adenovirus vector generates a large number of specific CD8⁺ T effector memory (TEM) cells that provide long-term immunity against a variety of pathogens. In the present study, we initially characterized the frequency, phenotype, and function of these T cells in vaccinated mice that were subjected to infectious challenge with the human protozoan parasite Trypanosoma cruzi. We observed that the frequency of the specific CD8⁺ T cells in the spleens of the vaccinated mice increased after challenge. Specific TEM cells differentiated into cells with a KLRG1(High) CD27(Low) CD43(Low) CD183(Low)T-bet(High) Eomes(Low) phenotype and capable to produce simultaneously the antiparasitic mediators IFNγ and TNF. Using the gzmBCreERT2/ROSA26EYFP transgenic mouse line, in which the cells that express Granzyme B after immunization, are indelibly labeled with enhanced yellow fluorescent protein, we confirmed that CD8⁺ T cells present after challenge were indeed TEM cells that had been induced by vaccination. Subsequently, we observed that the in vivo increase in the frequency of the specific CD8⁺ T cells was not because of an anamnestic immune response. Most importantly, after challenge, the increase in the frequency of specific cells and the protective immunity they mediate were insensitive to treatment with the cytostatic toxic agent hydroxyurea. We have previously described that the administration of the drug FTY720, which reduces lymphocyte recirculation, severely impairs protective immunity, and our evidence supports the model that when large amounts of antigen-experienced CD8⁺ TEM cells are present after heterologous prime-boost vaccination, differentiation, and recirculation, rather than proliferation, are key for the resultant protective immunity.

[1]  Holly Janes,et al.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. , 2013, The New England journal of medicine.

[2]  S. Jameson,et al.  Transcriptional downregulation of S1pr1 is required for establishment of resident memory CD8+ T cells , 2013, Nature Immunology.

[3]  S. Jameson,et al.  Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. , 2013, Immunity.

[4]  S. Jameson,et al.  Effector-like CD8⁺ T cells in the memory population mediate potent protective immunity. , 2013, Immunity.

[5]  R. Gottardo,et al.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. , 2013, The Journal of infectious diseases.

[6]  B. Jensen,et al.  Qualitative and Quantitative Analysis of Adenovirus Type 5 Vector-Induced Memory CD8 T Cells: Not as Bad as Their Reputation , 2013, Journal of Virology.

[7]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[8]  M. Rodrigues,et al.  Relevance of long-lived CD8+ T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination , 2012, Front. Immun..

[9]  Jerome H. Kim,et al.  Human immunodeficiency virus vaccine trials. , 2012, Cold Spring Harbor perspectives in medicine.

[10]  M. Zilliox,et al.  Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors , 2012, Journal of Virology.

[11]  D. Barouch,et al.  Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors , 2012, Journal of Virology.

[12]  R. Gazzinelli,et al.  Pathogen-Induced Proapoptotic Phenotype and High CD95 (Fas) Expression Accompany a Suboptimal CD8+ T-Cell Response: Reversal by Adenoviral Vaccine , 2012, PLoS pathogens.

[13]  A. Machado,et al.  Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi. , 2012, Vaccine.

[14]  Allan C. deCamp,et al.  HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable , 2011, The Journal of Immunology.

[15]  R. Gazzinelli,et al.  Subdominant/Cryptic CD8 T Cell Epitopes Contribute to Resistance against Experimental Infection with a Human Protozoan Parasite , 2011, PloS one.

[16]  A. Hill,et al.  Viral vectors as vaccine platforms: deployment in sight. , 2011, Current opinion in immunology.

[17]  R. Gazzinelli,et al.  Heterologous Plasmid DNA Prime-Recombinant Human Adenovirus 5 Boost Vaccination Generates a Stable Pool of Protective Long-Lived CD8+ T Effector Memory Cells Specific for a Human Parasite, Trypanosoma cruzi , 2011, Infection and Immunity.

[18]  R. Koup,et al.  Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa , 2010, PloS one.

[19]  J. Kappes,et al.  Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination , 2010, Journal of Virology.

[20]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[21]  A. Folgori,et al.  Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.

[22]  F. Tzelepis,et al.  Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. , 2009, Vaccine.

[23]  I. Ramshaw,et al.  Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity , 2009, Expert review of vaccines.

[24]  R. Gazzinelli,et al.  Perforin and Gamma Interferon Expression Are Required for CD4+ and CD8+ T-Cell-Dependent Protective Immunity against a Human Parasite, Trypanosoma cruzi, Elicited by Heterologous Plasmid DNA Prime-Recombinant Adenovirus 5 Boost Vaccination , 2009, Infection and Immunity.

[25]  H. Ertl,et al.  New insights on adenovirus as vaccine vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. Fearon,et al.  Secondary Replicative Function of CD8+ T Cells That Had Developed an Effector Phenotype , 2009, Science.

[27]  Alan D. Roberts,et al.  Activation phenotype, rather than central– or effector–memory phenotype, predicts the recall efficacy of memory CD8+ T cells , 2007, The Journal of experimental medicine.

[28]  R. Gazzinelli,et al.  Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. , 2006, Human gene therapy.

[29]  D. Klatzmann,et al.  Turning immunological memory into amnesia by depletion of dividing T cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Milon,et al.  Early Self-Regulatory Mechanisms Control the Magnitude of CD8+ T Cell Responses Against Liver Stages of Murine Malaria1 , 2003, The Journal of Immunology.

[31]  S. Boscardin,et al.  Immunization with cDNA Expressed by Amastigotes of Trypanosoma cruzi Elicits Protective Immune Response against Experimental Infection , 2003, Infection and Immunity.

[32]  E. Pamer,et al.  Feedback regulation of pathogen-specific T cell priming. , 2003, Immunity.

[33]  M. Tsuji,et al.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.